These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35804621)

  • 21. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle.
    Bertoldo F; Santini D; Lo Cascio V
    Nat Clin Pract Oncol; 2007 Dec; 4(12):711-21. PubMed ID: 18037875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton.
    Rogers MJ; Mönkkönen J; Munoz MA
    Bone; 2020 Oct; 139():115493. PubMed ID: 32569873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates and connexin 43: a critical review of evidence.
    Sadr-Eshkevari P; Ashnagar S; Rashad A; Dietz M; Jackowski J; Abdulazim A; Prochnow N
    Cell Commun Adhes; 2014 Oct; 21(5):241-7. PubMed ID: 24946183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor effects of bisphosphonates.
    Green JR
    Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG; Rogers MJ
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Curr Rheumatol Rep; 2003 Feb; 5(1):65-74. PubMed ID: 12590887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw.
    Srivichit B; Thonusin C; Chattipakorn N; Chattipakorn SC
    Arch Toxicol; 2022 May; 96(5):1227-1255. PubMed ID: 35199244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells.
    Abe K; Yoshimura Y; Deyama Y; Kikuiri T; Hasegawa T; Tei K; Shinoda H; Suzuki K; Kitagawa Y
    Int J Mol Med; 2012 Jun; 29(6):1007-15. PubMed ID: 22447156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Roles of Small GTPases in Osteoclast Biology.
    Weivoda MM; Oursler MJ
    Orthop Muscular Syst; 2014; 3():. PubMed ID: 25599004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates Targeting Ion Channels and Musculoskeletal Effects.
    Scala R; Maqoud F; Antonacci M; Dibenedetto JR; Perrone MG; Scilimati A; Castillo K; Latorre R; Conte D; Bendahhou S; Tricarico D
    Front Pharmacol; 2022; 13():837534. PubMed ID: 35370739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonates: how do they work?
    Papapoulos SE
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage.
    Nyman JS; Yeh OC; Hazelwood SJ; Martin RB
    Bone; 2004 Jul; 35(1):296-305. PubMed ID: 15207770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bone Cell Biology Assessed by Microscopic Approach. The effects of bisphosphonates on bone remodeling, microdamage accumulation and fracture repair process].
    Mashiba T
    Clin Calcium; 2015 Oct; 25(10):1537-40. PubMed ID: 26412734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
    McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
    Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.
    Flanagan AM; Chambers TJ
    Calcif Tissue Int; 1991 Dec; 49(6):407-15. PubMed ID: 1840176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoclast depletion with clodronate liposomes delays fracture healing in mice.
    Lin HN; O'Connor JP
    J Orthop Res; 2017 Aug; 35(8):1699-1706. PubMed ID: 27653179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonates reduce biomaterial turnover in healing of critical-size rat femoral defects.
    Hauser M; Siegrist M; Denzer A; Saulacic N; Grosjean J; Bohner M; Hofstetter W
    J Orthop Surg (Hong Kong); 2018; 26(3):2309499018802487. PubMed ID: 30270749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.